ME Therapeutics Holding (FRA:Q9T) EV-to-EBIT : -189.62 (As of May. 24, 2025)

ME Therapeutics Holding EV-to-EBIT Chart

ME Therapeutics Holding Quarterly Data
	Aug22	Dec22	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
EV-to-EBIT	Get a 7-Day Free Trial					-14.82	-31.31	-52.33	-75.60	-168.85

Competitive Comparison of ME Therapeutics Holding's EV-to-EBIT

For the Biotechnology subindustry, ME Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's EV-to-EBIT falls into.

ME Therapeutics Holding EV-to-EBIT Calculation

ME Therapeutics Holding's EV-to-EBIT for today is calculated as:

ME Therapeutics Holding's current Enterprise Value is €166.29 Mil.
ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (FRA:Q9T) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ME Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2025 is calculated as:

ME Therapeutics Holding's Enterprise Value for the quarter that ended in Feb. 2025 was €131.87 Mil.
ME Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding Business Description